Federico Serana

IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.

Decreased type I interferon receptor-soluble isoform in antiretroviral-treated HIV-positive children.

Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.

Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion.

Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.

Thymic and bone marrow output in patients with common variable immunodeficiency.

Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients.

Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.

Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients.

Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.

Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies.

Modulation of Regulatory T-Cell Subsets in Very Long-Term Treated Aviremic HIV(+) Patients and Untreated Viremic Patients.

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

T-cell Receptor and K-deleting Recombination Excision Circles in Newborn Screening of T- and B-cell Defects: Review of the Literature and Future Challenges.